Home » Stocks » Turning Point Therapeutics

Turning Point Therapeutics, Inc. (TPTX)

Stock Price: $61.22 USD -1.56 (-2.48%)
Updated Jul 9, 2020 2:51 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.20B
Revenue (ttm) n/a
Net Income (ttm) -119.30M
Shares Out 41.34M
EPS (ttm) -3.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $61.22
Previous Close $62.77
Change ($) -1.56
Change (%) -2.48%
Day's Open 63.01
Day's Range 59.57 - 63.66
Day's Volume 148,329
52-Week Range 31.30 - 72.03

More Stats

Market Cap 2.20B
Enterprise Value 1.82B
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 41.34M
Float 25.80M
EPS (basic) -3.47
EPS (diluted) -3.70
FCF / Share -2.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.74M
Short Ratio 4.72
Short % of Float 9.43%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.97
Revenue n/a
Operating Income -126.29M
Net Income -119.30M
Free Cash Flow -77.60M
Net Cash 376.02M
Net Cash / Share 10.47
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -23.81%
ROE -51.03%
ROIC -41.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$79.50*
(29.87% upside)
Low
67.0
Current: 61.22
High
88.0
Target: 79.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-77.72-25.64-16.73
Net Income-72.13-24.79-16.59
Shares Outstanding24.123.393.34
Earnings Per Share-2.99-7.31-4.97
Operating Cash Flow-57.76-23.53-12.64
Capital Expenditures-1.74-0.30-0.09
Free Cash Flow-59.50-23.84-12.73
Cash & Equivalents40910145.03
Total Debt5.06--
Net Cash / Debt40410145.03
Assets42210345.91
Liabilities17.8515270.75
Book Value404-48.41-24.84
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Turning Point Therapeutics, Inc.
Country United States
Employees 102
CEO Athena Countouriotis

Stock Information

Ticker Symbol TPTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TPTX
IPO Date October 4, 2006

Description

Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.